229 results
8-K
EX-10.2
BAX
Baxter International Inc.
21 Mar 24
Entry into a Material Definitive Agreement
4:32pm
to time, or (c) to be a commitment or any other undertaking or expression of any willingness to engage in any further discussion with the Borrower
8-K
EX-10.1
BAX
Baxter International Inc.
21 Mar 24
Entry into a Material Definitive Agreement
4:32pm
, supplemented or modified from time to time, or (c) to be a commitment or any other undertaking or expression of any willingness to engage in any further
8-K
yok9f7pyws14q
4 Mar 24
Regulation FD Disclosure
8:30am
8-K
EX-99.1
i9p2ua1i v4f5qkly
8 Feb 24
Baxter Reports Fourth-quarter and Full-year 2023 Results
7:18am
8-K
EX-99.1
dnaa24am4khlkcrbnvei
27 Jul 23
Baxter Reports Second-quarter 2023 Results
7:33am
8-K
EX-99.1
ifewz5eipo9qtyl5ea2o
6 Jul 23
Regulation FD Disclosure
8:30am
8-K
EX-99.1
6lwhksst
9 May 23
Baxter Signs Definitive Agreement to Divest its BioPharma Solutions Business to
8:42am
8-K
EX-2.1
wigbk51myg lfmm
9 May 23
Baxter Signs Definitive Agreement to Divest its BioPharma Solutions Business to
8:42am
8-K
EX-3.1
o7w m7k3sjv14s
9 May 23
Baxter Signs Definitive Agreement to Divest its BioPharma Solutions Business to
8:42am
8-K
EX-99.1
2gpt zdovermkd0to6l
27 Oct 22
Baxter Reports Third-quarter 2022 Results
7:18am
8-K
EX-10.2
5qgx8my
30 Sep 22
Entry into a Material Definitive Agreement
4:16pm
8-K
EX-10.1
jzljml6i4xmly2n
30 Sep 22
Entry into a Material Definitive Agreement
4:16pm